A full online version of The Novozymes Report 2017, featuring interactive graphics, is available at report2017.novozymes.com.
Editor in chief
Anja Berg Winther, Global Communications
email@example.com | tel. +45 3077 0421
Elsebeth Gylling Kjærsgaard, Investor Relations
firstname.lastname@example.org | tel. +45 3077 2510
The editorial team from Novozymes, headed by Global Communications
Lars Just and Thorbjørn Hansen
Design & web
Editing & proofreading
Reporting and audits
The website contains The Novozymes Report 2017 – which, pursuant to section 149 of the Danish Financial Statements Act, is an extract of the company's annual report – and the financial statements of the parent company Novozymes A/S. Together, these form the company’s annual report that is filed with the Danish Business Authority.
PwC has audited the consolidated financial statements, the parent company financial statements, and the environmental and social data. PwC has also been the sustainability assurance provider, basing its assurance on the AA1000 Assurance Standard (2008).
The audit covers financial, environmental and social data. These are marked “Audited by PwC.” See also the statements in the report.
PwC has not audited the sections of the report found under the headings The big picture, Our business, Governance and Sustainability. The Sustainability section includes our Communication on Progress with respect to the UN Global Compact principles, our report index based on the Global Reporting Initiative (GRI), as well as detailed sustainability data from our main activities in Argentina, Brazil, Canada, China, Denmark, India, the UK and the US.
The report has been prepared in accordance with International Financial Reporting Standards (IFRS), the Danish Financial Statements Act and the additional requirements of Nasdaq Copenhagen A/S for the presentation of financial statements by listed companies. It has also been inspired by the GRI's G4 Sustainability Reporting Guidelines. See Basis of reporting in the report for more details.
This annual report contains forward-looking statements, including statements about future events, future financial performance, plans, strategies and expectations. Forward-looking statements are associated with words such as, but not limited to, "believe," "anticipate," "expect," "estimate," "intend," "plan," "project," "could," "may," "might" and other words of similar meaning.
Forward-looking statements are by their very nature associated with risks and uncertainties that may cause actual results to differ materially from expectations, both positively and negatively. The risks and uncertainties may, among other things, include unexpected developments in i) the ability to develop and market new products; ii) the demand for Novozymes’ products, market-driven price decreases, industry consolidation, and launches of competing products or disruptive technologies in Novozymes’ core areas; iii) the ability to protect and enforce the company’s intellectual property rights; iv) significant litigation or breaches of contract; v) the materialization of the company’s growth platforms, notably the opportunity for marketing biomass conversion technologies or the development of microbial solutions for broad-acre crops; vi) political conditions, such as acceptance of enzymes produced by genetically modified organisms; vii) global economic and capital market conditions, including, but not limited to, currency exchange rates (USD/DKK and EUR/DKK in particular, but not exclusively), interest rates and inflation; viii) significant price decreases for inputs and materials that compete with Novozymes’ biological solutions. The company undertakes no duty to update any forward-looking statements as a result of future developments or new information.